AMM 215: Lanluma Collagen Stimulator Yields Promising Results
September 28, 2024
This episode delves into the latest clinical outcomes of Lanluma®, an injectable poly-L-lactic acid-based collagen stimulator, as revealed by a recent post-market study. Listeners will learn about the trial’s methodology, participant experiences, and the areas treated, along with the adverse events reported. The episode also covers the overall satisfaction expressed by both investigators and participants, highlighting the product’s effectiveness. Upcoming evaluations in the ongoing 25-month follow-up are expected to provide further insights. Stay tuned for a detailed update on advancements in aesthetic medicine.
Quick Takes
- New clinical outcomes for Lanluma® showed promising results in soft tissue augmentation
- Seventy participants underwent 99 treatment sessions across various body areas
- No severe or serious side effects reported with high satisfaction from investigators and participants
Episode Transcript
Today is September 28, 2024. New clinical outcomes for an innovative injectable poly-L-lactic acid-based collagen stimulator known as Lanluma® have shown promising results in a recent post-market study. This trial, which began a year ago, aimed to assess the safety and effectiveness of Lanluma® for soft tissue augmentation over a nine-month period.
Seventy participants underwent 99 treatment sessions across various body areas, including the neck, upper arm, hand, thigh, and décolleté. Notably, the most common adverse events were lumps and nodules in areas like the neck and hand. Importantly, no severe or serious side effects were reported.
Both investigators and participants expressed high satisfaction with the treatments across all five body areas. These positive results highlight the product’s effectiveness and adherence to best practices in its application. Further evaluation is expected in the ongoing 25-month follow-up, which will provide more comprehensive insights.
That’s the latest in aesthetic medicine today!